
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9165045/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67, 1560-1599.	7.3	2,620
2	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	13.7	1,840
3	AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63, 261-283.	7.3	1,662
4	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, 149, 649-659.	1.3	725
5	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	5.8	509
6	Hepatitis C virus infection. Nature Reviews Disease Primers, 2017, 3, 17006.	30.5	354
7	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. Gastroenterology, 2015, 148, 100-107.e1.	1.3	307
8	Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology, 2018, 155, 422-430.e1.	1.3	263
9	Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology, 2001, 34, 411-416.	7.3	243
10	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	8.1	237
11	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	5.9	230
12	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology, 2020, 72, 539-557.	3.7	208
13	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology, 2016, 151, 1131-1140.e5.	1.3	199
14	Reduction in liver transplant waitâ€listing in the era of directâ€acting antiviral therapy. Hepatology, 2017, 65, 804-812.	7.3	197
15	Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplantation, 2012, 18, 716-726.	2.4	195
16	Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology, 2013, 57, 881-889.	7.3	195
17	Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clinical Liver Disease, 2018, 12, 33-34.	2.1	187
18	Sexual activity as a risk factor for hepatitis C. Hepatology, 2002, 36, s99-s105.	7.3	178

#	Article	IF	CITATIONS
19	Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	1.3	178
20	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology, 2016, 150, 419-429.	1.3	166
21	Sexual activity as a risk factor for hepatitis C. Hepatology, 2002, 36, S99-S105.	7.3	154
22	National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. JAMA Internal Medicine, 2019, 179, 340.	5.1	150
23	Safety and efficacy of current directâ€acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCVâ€TARGET study. Hepatology, 2017, 66, 1090-1101.	7.3	149
24	Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology, 2017, 65, 65-77.	7.3	134
25	The Epidemiology of Newly Diagnosed Chronic Liver Disease in Gastroenterology Practices in the United States: Results From Population-Based Surveillance. American Journal of Gastroenterology, 2008, 103, 2727-2736.	0.4	131
26	Treating hepatitis C infection in liver transplant recipients. Liver Transplantation, 2006, 12, 1192-1204.	2.4	123
27	Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. American Journal of Clinical Nutrition, 2019, 110, 139-149.	4.7	122
28	Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology, 1998, 27, 877-880.	7.3	121
29	Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation, 2007, 13, 122-129.	2.4	119
30	Alcohol use and hepatitis C. Hepatology, 2002, 36, S220-S225.	7.3	118
31	Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post–Liver Transplant Score. Hepatology, 2019, 69, 1477-1487.	7.3	111
32	Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology, 2017, 65, 2090-2099.	7.3	100
33	Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. Journal of Clinical Oncology, 2020, 38, 3698-3715.	1.6	99
34	The Changing Epidemiology andÂNatural History of Hepatitis C VirusÂInfection. Clinics in Liver Disease, 2006, 10, 697-715.	2.1	91
35	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	4.4	90
36	New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology, 2019, 156, 355-368.e3.	1.3	89

#	Article	IF	CITATIONS
37	Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology, 2008, 47, 1150-1157.	7.3	87
38	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. Journal of Hepatology, 2020, 73, 540-548.	3.7	85
39	Directâ€acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after localâ€regional therapy or liver transplant waitlist dropout. Hepatology, 2018, 68, 449-461.	7.3	84
40	Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2016, 111, 658-664.	0.4	80
41	Outcomes in liver transplantation: Does sex matter?. Journal of Hepatology, 2015, 62, 946-955.	3.7	79
42	Multicenter Validation of Association Between Decline in MRIâ€₽DFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	7.3	79
43	Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. Journal of Hepatology, 2020, 73, 516-522.	3.7	78
44	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation, 2017, 101, 945-955.	1.0	76
45	The option of HBIG-free prophylaxis against recurrent HBV. Journal of Hepatology, 2012, 56, 1189-1197.	3.7	75
46	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology, 2019, 156, 88-95.e5.	1.3	73
47	Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. The Lancet Gastroenterology and Hepatology, 2019, 4, 227-238.	8.1	72
48	The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 563-575.	4.5	68
49	Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transplantation, 2006, 12, 801-807.	2.4	67
50	Viral hepatitis and pregnancy. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 117-130.	17.8	66
51	Retail Alcohol and Tobacco Sales During COVID-19. Annals of Internal Medicine, 2021, 174, 1027-1029.	3.9	66
52	Hepatitis C therapy before and after liver transplantation. Liver Transplantation, 2008, 14, S58-S66.	2.4	64
53	Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017, 153, 1260-1272.e3.	1.3	57
54	Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 73, 318-365.	7.3	57

4

#	Article	IF	CITATIONS
55	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASLâ€AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092.	7.3	52
56	Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver International, 2020, 40, 355-359.	3.9	50
57	Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. American Journal of Gastroenterology, 2017, 112, 755-762.	0.4	49
58	Hepatitis C virus: Quantitation and distribution in liver. Journal of Medical Virology, 1997, 51, 217-224.	5.0	48
59	Benefits and risks of combination therapy for hepatitis B. Hepatology, 2009, 49, S122-S128.	7.3	47
60	Relationship between three commonly used nonâ€invasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonâ€alcoholic steatohepatitis. Liver International, 2019, 39, 924-932.	3.9	47
61	Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting. Clinical Infectious Diseases, 2015, 60, 108-116.	5.8	46
62	Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update. Journal of Hepatology, 2015, 62, 701-711.	3.7	44
63	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation, 2017, 101, 956-967.	1.0	44
64	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. Transplant International, 2019, 32, 1268-1276.	1.6	44
65	Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. Journal of Hepatology, 2019, 70, 126-132.	3.7	44
66	NAFLD and Alcoholâ€Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. Hepatology, 2021, 74, 3330-3344.	7.3	44
67	Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. American Journal of Gastroenterology, 2019, 114, 1283-1291.	0.4	41
68	Hepatitis C elimination: challenges with under-diagnosis and under-treatment. F1000Research, 2019, 8, 54.	1.6	40
69	Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. Gastroenterology, 2019, 157, 472-480.e5.	1.3	39
70	Hepatitis B immune globulin preparations and use in liver transplantation. Clinics in Liver Disease, 2003, 7, 537-550.	2.1	38
71	Body mass index trajectories in young adulthood predict nonâ€alcoholic fatty liver disease in middle age: The <scp>CARDIA</scp> cohort study. Liver International, 2018, 38, 706-714.	3.9	38
72	Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care. Hepatology Communications, 2019, 3, 20-28.	4.3	38

#	Article	IF	CITATIONS
73	Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study. Gastroenterology, 2020, 159, 1752-1762.e10.	1.3	38
74	Fibrosis Progression in African Americans and Caucasian Americans With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2008, 6, 1403-1411.	4.4	37
75	Total 25( <scp>OH</scp> ) vitamin D, free 25( <scp>OH</scp> ) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction. Liver International, 2015, 35, 2294-2300.	3.9	37
76	Entecavir and Peginterferon Alfaâ€⊋a in Adults With Hepatitis B e Antigen–Positive Immuneâ€Tolerant Chronic Hepatitis B Virus Infection. Hepatology, 2019, 69, 2338-2348.	7.3	37
77	Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCVâ€Viremic Donors. Hepatology, 2021, 73, 2110-2123.	7.3	37
78	Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men. Clinical Gastroenterology and Hepatology, 2021, 19, 400-402.e2.	4.4	37
79	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology, 2021, 74, 2395-2409.	7.3	36
80	Outcomes of Sleeve Gastrectomy in Obese Liver Transplant Candidates. Liver Transplantation, 2019, 25, 538-544.	2.4	35
81	A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!. Journal of Hepatology, 2018, 69, 767-768.	3.7	33
82	Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. Clinical Gastroenterology and Hepatology, 2020, 18, 188-195.e4.	4.4	33
83	Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database. Liver Transplantation, 2019, 25, 706-711.	2.4	30
84	Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. Journal of Hepatology, 2021, 74, 1355-1361.	3.7	30
85	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. Journal of Hepatology, 2021, 75, S178-S190.	3.7	30
86	Hepatitis C and hepatocellular carcinoma. Current Treatment Options in Oncology, 2001, 2, 473-483.	3.0	29
87	Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. American Journal of Transplantation, 2018, 18, 2506-2512.	4.7	29
88	Addressing Social Determinants of Liver Disease During the COVIDâ€19 Pandemic and Beyond: A Call to Action. Hepatology, 2021, 73, 811-820.	7.3	29
89	Difficultâ€ŧoâ€εure populations with chronic hepatitis c: Vanishing in the directâ€acting antiviral era?. Hepatology, 2015, 62, 4-7.	7.3	28
90	Evaluating Women's Preferences for Hepatitis C Treatment During Pregnancy. Hepatology Communications, 2018, 2, 1306-1310.	4.3	28

#	Article	IF	CITATIONS
91	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	4.4	28
92	Bariatric surgery to achieve transplant in end-stage organ disease patients: A systematic review and meta-analysis. American Journal of Surgery, 2020, 220, 566-579.	1.8	28
93	Outcomes of liver transplantation for acute fatty liver disease of pregnancy. American Journal of Transplantation, 2019, 19, 2101-2107.	4.7	27
94	Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2022, 20, 409-418.e5.	4.4	27
95	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. Journal of Hepatology, 2022, 77, 1670-1689.	3.7	26
96	Early liver transplantation for severe alcoholic hepatitis. Current Opinion in Organ Transplantation, 2018, 23, 229-236.	1.6	25
97	Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. Clinical Gastroenterology and Hepatology, 2021, 19, 1267-1274.e1.	4.4	25
98	Treatment of Recurrent Hepatitis C in Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2005, 3, S125-S131.	4.4	24
99	Management of hepatitis B in special populations. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 311-320.	2.4	24
100	Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States. Transplantation, 2020, 104, 2078-2086.	1.0	24
101	Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B. PLoS Pathogens, 2019, 15, e1007715.	4.7	23
102	Sex Hormone–Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. American Journal of Gastroenterology, 2019, 114, 758-763.	0.4	23
103	Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B. JAMA Oncology, 2019, 5, 17.	7.1	23
104	Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population. Clinical Gastroenterology and Hepatology, 2021, 19, 1258-1266.e1.	4.4	23
105	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology, 2021, 73, 2124-2140.	7.3	23
106	Antibody to GBV-C second envelope glycoprotein (anti-GBV-C E2): Is it a marker for immunity?. Journal of Medical Virology, 1997, 53, 354-360.	5.0	22
107	Research methodologies to address clinical unmet needs and challenges in alcoholâ€associated liver disease. Hepatology, 2022, 75, 1026-1037.	7.3	22
108	Clinician assessments of health status predict mortality in patients with endâ€stage liver disease awaiting liver transplantation. Liver International, 2015, 35, 2167-2173.	3.9	21

#	Article	IF	CITATIONS
109	Current Management of Hepatitis C Virus. Clinics in Liver Disease, 2015, 19, 669-688.	2.1	21
110	Antienvelope antibodies are protective against GBV-C reinfection: Evidence from the liver transplant model. Journal of Medical Virology, 1998, 56, 253-258.	5.0	20
111	Individualizing hepatitis B infection prophylaxis in liver transplant recipients. Journal of Hepatology, 2011, 55, 507-509.	3.7	20
112	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1811-1819.e4.	4.4	20
113	Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation, 2020, 104, 476-481.	1.0	20
114	Superior Waitâ€List Outcomes in Patients with Alcoholâ€Associated Liver Disease Compared With Other Indications for Liver Transplantation. Liver Transplantation, 2019, 25, 1310-1320.	2.4	19
115	Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. American Journal of Transplantation, 2021, 21, 3148-3156.	4.7	18
116	Women with Cirrhosis. Gastroenterology Clinics of North America, 2016, 45, 345-358.	2.2	17
117	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 856-865.	2.0	17
118	Clinical Research in Hepatology in the COVIDâ€19 Pandemic and Postâ€Pandemic Era: Challenges and the Need for Innovation. Hepatology, 2020, 72, 1819-1837.	7.3	17
119	Pregnancy-Associated Liver Diseases. Gastroenterology, 2022, 163, 97-117.e1.	1.3	17
120	Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology, 2015, 61, 1747-1754.	7.3	16
121	Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients. Liver Transplantation, 2015, 21, 272-274.	2.4	16
122	Medicaid Policy and Liver Transplant for Alcoholâ€Associated Liver Disease. Hepatology, 2020, 72, 130-139.	7.3	16
123	Mortality in adults with chronic hepatitis B infection in the United States: a populationâ€based study. Alimentary Pharmacology and Therapeutics, 2020, 52, 382-389.	3.7	15
124	Liver transplantation as therapy for hepatocellular carcinoma. Liver International, 2020, 40, 116-121.	3.9	15
125	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight, 2021, 6, .	5.0	15
126	Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B. Hepatology Communications, 2022, 6, 935-949.	4.3	15

#	Article	IF	CITATIONS
127	Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. Digestive Diseases and Sciences, 2016, 61, 62-69.	2.3	14
128	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant. American Journal of Transplantation, 2021, 21, 1780-1788.	4.7	14
129	Artificial intelligence to identify harmful alcohol use after early liver transplant for alcohol-associated hepatitis. American Journal of Transplantation, 2022, 22, 1834-1841.	4.7	14
130	KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. American Journal of Kidney Diseases, 2020, 75, 665-683.	1.9	13
131	Incidence and prediction of HBsAg seroclearance in a prospective multiâ€ethnic HBeAgâ€negative chronic hepatitis B cohort. Hepatology, 2022, 75, 709-723.	7.3	13
132	Liver Transplantation in Unauthorized Immigrants in the United States. Hepatology, 2020, 71, 1802-1812.	7.3	12
133	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation, 2020, 104, 2087-2096.	1.0	12
134	Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectrum, 2021, 5, pkaa100.	2.9	12
135	Twentyâ€fiveâ€year trajectories of insulin resistance and pancreatic βâ€cell response and diabetes risk in nonalcoholic fatty liver disease. Liver International, 2018, 38, 2069-2081.	3.9	11
136	Use of a hepatitis C virus ( <scp>HCV</scp> ) <scp>RNA</scp> â€positive donor in a treated <scp>HCV RNA</scp> â€negative liver transplant recipient. Transplant Infectious Disease, 2018, 20, e12809.	1.7	11
137	Trends in Hepatitis B Infection and Immunity Among Women of Childbearing Age in the United States. Clinical Infectious Diseases, 2020, 71, 586-592.	5.8	11
138	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	7.3	11
139	Changes and mediators of survival disparity among Black liver transplant recipients in the United States. American Journal of Transplantation, 2021, 21, 3883-3893.	4.7	11
140	Obesity as an isolated contraindication to kidney transplantation in the endâ€stage renal disease population: A cohort study. Obesity, 2021, 29, 1538-1546.	3.0	11
141	Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. American Journal of Gastroenterology, 2022, 117, 433-444.	0.4	10
142	Combined Interferon and Lamivudine Therapy: Is This The Treatment of Choice for Patients With Chronic Hepatitis B Virus Infection?. Hepatology, 2003, 32, 675-677.	7.3	9
143	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‶ARGET Analysis. Hepatology Communications, 2019, 3, 1388-1399.	4.3	9
144	Excess Mortality After Liver Transplantation in Young Women With Alcohol-Associated Liver Disease. American Journal of Gastroenterology, 2021, 116, 551-559.	0.4	9

#	Article	IF	CITATIONS
145	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease ( <scp>NAFLD</scp> ). Alimentary Pharmacology and Therapeutics, 2022, 55, 1441-1451.	3.7	9
146	Alcohol use trajectories among U.S. adults during the first 42Âweeks of the COVIDâ€19 pandemic. Alcoholism: Clinical and Experimental Research, 2022, 46, 1062-1072.	2.4	9
147	Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2016, 20, 365-385.	2.1	8
148	Return to Alcohol Use After Liver Transplant: Patterns and Surveillance. Clinical Liver Disease, 2018, 12, 160-164.	2.1	8
149	Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications. American Journal of Transplantation, 2021, 21, 3324-3332.	4.7	8
150	The corrected donor age for hepatitis C virus–infected liver transplant recipients. Liver Transplantation, 2015, 21, 1022-1030.	2.4	7
151	Is Low Level Viremia Acceptable During Antiviral Therapy of Patients With HBV Infection and Decompensated Cirrhosis?. Clinical Gastroenterology and Hepatology, 2018, 16, 1876-1878.	4.4	7
152	Enhanced Screening for Hepatitis D in the USA: Overcoming theÂDeltaÂBlues. Digestive Diseases and Sciences, 2021, 66, 2483-2485.	2.3	7
153	Optimizing the preâ€referral workup for gastroenterology and hepatology specialty care: consensus using the D elphi method. Journal of Evaluation in Clinical Practice, 2016, 22, 46-52.	1.8	6
154	Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clinical Transplantation, 2016, 30, 1140-1145.	1.6	6
155	Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?. AME Medical Journal, 2018, 3, 27-27.	0.4	6
156	Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. Annals of Hepatology, 2020, 19, 437-445.	1.5	6
157	Hepatitis C Screening Rates and Care Cascade in a Large US Insured Population, 2010–2016: Gaps to Elimination. Population Health Management, 2021, 24, 198-206.	1.7	6
158	Diverging Incidence Trends for Hepatocellular Carcinoma in Rural and Urban Settings in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 1180-1185.e2.	4.4	6
159	Liver-related mortality in the United States: hepatitis C declines, non-alcoholic fatty liver and alcohol rise. Translational Gastroenterology and Hepatology, 2019, 4, 19-19.	3.0	5
160	Intentional Transmission of Hepatitis C With Organ Transplantation: With Opportunity Comes Responsibility. Transplantation, 2019, 103, 2215-2216.	1.0	5
161	Adherence to pregnancy hepatitis B care guidelines in women and infants in the United States and evaluation of two interventions to improve care: A multicentre hospitalâ€based study. Journal of Viral Hepatitis, 2021, 28, 582-591.	2.0	5
162	Geographic hotspot detection for late-stage hepatocellular carcinoma: novel approach to cancer control. Cancer Causes and Control, 2022, 33, 701-710.	1.8	5

#	Article	IF	CITATIONS
163	Motion – The Available Treatments for Hepatits C Are Cost Effective: Arguments for the Motion. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 705-709.	1.7	4
164	Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. Journal of Immunology, 2018, 200, 1124-1132.	0.8	4
165	The Internet as a Tool for Liver Transplant Programs to Combat Stigma Related to Alcohol Use Disorder. Hepatology Communications, 2021, 5, 155-157.	4.3	4
166	Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. Journal of General Internal Medicine, 2022, 37, 3435-3443.	2.6	4
167	Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival. Clinical Gastroenterology and Hepatology, 2015, 13, 2002-2004.	4.4	3
168	Increasing burden of cirrhosis projected to 2040 in Canada: implications for prevention, screening, and management. Journal of Hepatology, 2020, 73, S45.	3.7	3
169	Use of Hepatitis B Virus–Positive Organs in Organ Transplantation. Clinics in Liver Disease, 2021, 25, 841-857.	2.1	3
170	The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. , 2018, 1, 24-33.		3
171	Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. Liver International, 2009, 29, 1178-1183.	3.9	2
172	Response to clinical assessments of health status as a potential marker to identify patients who are too sick to undergo transplantation. Liver International, 2016, 36, 611-611.	3.9	2
173	Reply. Hepatology, 2018, 68, 1658-1660.	7.3	2
174	Prior Bariatric Surgery in Liver Transplant Candidates: Unforeseen Consequences?. Liver Transplantation, 2019, 25, 203-204.	2.4	2
175	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. Clinical Gastroenterology and Hepatology, 2020, 18, 259-261.	4.4	2
176	Caesarean section or nonâ€breastfeeding for prevention of MTCT—beware of sending the wrong message. Journal of Viral Hepatitis, 2021, 28, 575-576.	2.0	2
177	Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons. AIDS Research and Human Retroviruses, 2021, 37, 534-541.	1.1	2
178	Hepatitis C virus: Quantitation and distribution in liver. Journal of Medical Virology, 1997, 51, 217-224.	5.0	2
179	Antibody to GBV  second envelope glycoprotein (antiâ€GBV  E2): Is it a marker for immunity?. Journal of Medical Virology, 1997, 53, 354-360.	5.0	2
180	Rising Healthcare Costs and Utilization among Young Adults with Cirrhosis in Ontario: A Population-Based Study. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-13.	1.9	2

#	Article	IF	CITATIONS
181	Pregnancy Is Not Associated with an Increased Risk of Decompensation, Transplant, or Death in Compensated Cirrhosis. International Journal of Hepatology, 2022, 2022, 1-8.	1.1	2
182	Chronic hepatitis B. Current Treatment Options in Gastroenterology, 2001, 4, 493-502.	0.8	1
183	Treatment of chronic hepatitis B. Current Hepatitis Reports, 2003, 2, 49-59.	0.3	1
184	Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 293.	1.3	1
185	Use of hepatitis C viraemic organs in kidney transplantation: a need to hit the pause button?. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 5-6.	17.8	1
186	Expanding the use of hepatitis C–positive donors and keeping recipient safety at the forefront. American Journal of Transplantation, 2020, 20, 627-628.	4.7	1
187	Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/Râ^' Transplants. Hepatology, 2020, 72, 787-787.	7.3	1
188	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep, 2021, 3, 196-208.	0.6	1
189	Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. AIDS Reviews, 2016, 18, 81-8.	1.0	1
190	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology, 2017, 16, 375-381.	1.5	1
191	Advocacy for Equity in Transplantation Access for Alcohol-Associated Liver Disease: How Research Changed Medi-Cal Policy. Gastroenterology, 2022, 163, 539-542.	1.3	1
192	The changing â€~face' of wait-listed patients in the USA. Current Opinion in Organ Transplantation, 2016, 21, 89-90.	1.6	0
193	Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series. Clinical Transplantation, 2018, 32, e13303.	1.6	0
194	Selective use of liver transplantation for severe alcohol-associated hepatitis. Expert Review of Gastroenterology and Hepatology, 2020, 14, 175-184.	3.0	0
195	Transplanting Kidneys From Donors With Chronic Hepatitis B: Bringing Transmission Risk Closer to Zero. Clinical Infectious Diseases, 2021, 72, 1024-1025.	5.8	0
196	Treatment of HCV, HDV, or HIV Coinfections. , 2021, , 339-373.		0
197	Reply to â€~Evidence against in utero transmission of hepatitis B virus'. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 445-446.	17.8	0
198	Transplantation, HIV Serostatus and Registry Data, Room for Improvement. American Journal of Transplantation, 2022, , .	4.7	0

#	Article	IF	CITATIONS
199	Breakthroughs in hepatology. Journal of Hepatology, 2022, 76, 1247-1248.	3.7	0
200	Letter: nonâ€invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> —not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0